Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Enterprise Value (2020 - 2025)

Apellis Pharmaceuticals has reported Enterprise Value over the past 6 years, most recently at -$467.7 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$467.7 million for Q4 2025, down 13.36% from a year ago — trailing twelve months through Dec 2025 was -$467.7 million (down 13.36% YoY), and the annual figure for FY2025 was -$467.7 million, down 13.36%.
  • Enterprise Value for Q4 2025 was -$467.7 million at Apellis Pharmaceuticals, up from -$480.6 million in the prior quarter.
  • Over the last five years, Enterprise Value for APLS hit a ceiling of -$272.3 million in Q2 2021 and a floor of -$766.4 million in Q1 2023.
  • Median Enterprise Value over the past 5 years was -$460.6 million (2023), compared with a mean of -$486.5 million.
  • Biggest five-year swings in Enterprise Value: skyrocketed 67.3% in 2021 and later crashed 122.43% in 2022.
  • Apellis Pharmaceuticals' Enterprise Value stood at -$700.6 million in 2021, then increased by 21.05% to -$553.1 million in 2022, then skyrocketed by 36.3% to -$352.3 million in 2023, then decreased by 17.12% to -$412.6 million in 2024, then decreased by 13.36% to -$467.7 million in 2025.
  • The last three reported values for Enterprise Value were -$467.7 million (Q4 2025), -$480.6 million (Q3 2025), and -$371.5 million (Q2 2025) per Business Quant data.